Related Experiment Videos
Prognostic factors for mesothelioma
1Bart's Mesothelioma Research Group, St. Bartholomew's Hospital and Medical College, London EC1A 7BE, UK. jeremy.steele@bartsandthelondon.nhs.uk
Hematology/Oncology Clinics of North America
|December 6, 2005
Summary
Prognosis for malignant mesothelioma remains poor, but patient selection is key. Identifying prognostic factors and molecular data improves treatment targeting and patient outcomes.
Area of Science:
- Oncology
- Medical Genetics
Background:
- Malignant mesothelioma understanding has advanced, yet prognosis remains poor for most patients.
- Current treatments like radical surgery and palliative chemotherapy have limitations and potential toxicities.
Purpose of the Study:
- To identify crucial prognostic factors for patient selection in malignant mesothelioma.
- To explore the role of genetic factors in predicting clinical outcomes and guiding treatment.
Main Methods:
- Review of recent advancements in understanding malignant mesothelioma.
- Analysis of clinical data to identify factors associated with longer survival.
- Identification and correlation of significant genes with clinical outcomes.
Main Results:
- Key prognostic factors for longer survival include epithelioid histology, earlier stage, female gender, left-sided primary, non-exposure to asbestos, non-smoking history, and absence of symptoms.
- Numerous genes of significance have been identified and correlated with clinical outcomes.
Conclusions:
- Patient selection is critical for effective treatment of malignant mesothelioma.
- Molecular data offers high accuracy for prognostication, biological insights, and novel therapeutic targets.